|
|
|
|
BOARD OF DIRECTORS
 |
Robert Moses
Chairman
Robert (Bob) W Moses is the Chairman of the company’s Board of Directors and is also Chairman of the Remuneration Committee and a member of the Audit Committee. Formerly Vice President of CSL Limited, Bob draws on more than 35 years experience in the pharmaceutical/biotechnology industry. During the period 1993-2001, Bob played a central role in CSL’s development internationally. Prior to joining CSL, Bob was Managing Director of commercial law firm Freehills, Chairman and CEO of a NASDAQ listed medical service company and Corporate Manager of New Business Development at ICI (now Orica). Bob also spent 17 years in various management roles at the multinational pharmaceutical company Eli Lilly. He is currently non-executive Chairman of the Australian Stem Cell Centre Limited, TGR Biosciences Pty Ltd, Sylvan Scientific Limited and the CRC for Chronic Inflammatory Diseases, as well as commercial consultant to the Murdoch Childrens Research Institute. During the past three years Mr Moses has also served as Chairman of Meditech Research Limited and Amrad Corporation Limited.
|
 |
Dr Chris Belyea
Non-Executive Director
Chris Belyea, a non-executive director of the company, is Chairman of the Audit Committee and a member of the Remuneration Committee. Chris has a PhD in physics from the University of Melbourne and is a registered patent attorney. He became the founding CEO of Antisense Therapeutics in November 2000 and remained in this role until January 2002 (shortly after Antisense Therapeutics was listed on the Australian Stock Exchange). He worked for the Australian patent firm Griffith Hack & Co for 5 years before joining Circadian Technologies Limited as its Licensing and Projects Manager in 1996. In 1998 Dr Belyea became founding CEO and member of the board of Metabolic Pharmaceuticals Limited, which is developing drugs for obesity and other diseases. He is currently Chief Scientific Officer and member of the board of Metabolic Pharmaceuticals. During the past three years Dr Belyea has served as an executive director of Metabolic Pharmaceuticals Ltd.
|
 |
Mark Diamond
Managing Director
Mark has over 20 years experience in the pharmaceutical and biotechnology industry. Before joining Antisense Therapeutics in 2001 as CEO, Mark was employed in the US as Director, Product Planning/Business Development at Faulding Pharmaceuticals. Prior to this he held the positions of Senior Manager, Business Development and In-licensing within Faulding's European operation based in the UK and International Business Development Manager with Faulding in Australia. Mark has a BSc from Monash University Victoria and an MBA from Macquarie University in NSW. |
|
|
 |
Prof Graham Mitchell
Non-Executive Director
Graham Mitchell is a non-executive director of the company and a member of its Remuneration Committee. He is an advisor in Science, Engineering and Technology to the Victorian Government. In another government role the principals of Foursight Associates, including Professor Mitchell, jointly act as Chief Scientist for the Department of Primary Industries and Department of Sustainability and Environment. Graham is a non-executive director of Compumedics Limited, AVS Pty Ltd, the Geoffrey Gardiner Dairy Foundation and is a principal of Foursight Associates Pty Ltd. He is a Professorial Associate of the University of Melbourne. Professor Mitchell has held the position of Director of Research in the R&D Division of CSL Limited and for many years was a research scientist at the Walter & Eliza Hall Institute. During the past three years Professor Mitchell has served as a non-executive director of Compumedics Limited.
|
 |
Prof George Werther
Non-Executive Director
George Werther is a non-executive director of the company and a member of its Remuneration and Audit Committees. George is Director of the Department of Endocrinology and Diabetes at the Royal Children's Hospital, and the Centre for Hormone Research at the hospital's Murdoch Childrens Research Institute, where he also serves on its Commercialisation Committee. He has served on many national and international scientific committees, and peer review bodies, and is on the editorial board of two international scientific journals. He is the Chairman of the Scientific Advisory Board for Neuren Pharmaceuticals. He was on the council of the Australasian Paediatric Endocrine Group and was a board director of the Australia MedicAlert Foundation. He is also a Professorial Fellow at the University of Melbourne.
|
|
|
|
|
